<SEC-DOCUMENT>0001193125-16-797965.txt : 20161220
<SEC-HEADER>0001193125-16-797965.hdr.sgml : 20161220
<ACCEPTANCE-DATETIME>20161220083502
ACCESSION NUMBER:		0001193125-16-797965
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20161219
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161220
DATE AS OF CHANGE:		20161220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			pSivida Corp.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		162060327

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d318583d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION&nbsp;13 OR 15(D) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;19, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>pSivida Corp. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-51122</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-2774444</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>480 Pleasant Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Watertown, MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02472</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code:&nbsp;(617) 926-5000 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report.) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;19, 2016, pSivida Corp. (the &#147;Company&#148;) distributed a letter to the Company&#146;s investors email distribution list
discussing its recent changes to the Company&#146;s leadership team and its future plans for research, development and commercialization. A copy of the letter is attached as Exhibit 99.1 hereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various statements made in the letter are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate
assumptions. All statements that address activities, events or developments that the Company intends, expects or believes may occur in the future are forward-looking statements. Some of the factors that could cause actual results to differ
materially from the anticipated results or other expectations expressed, anticipated or implied in the Company&#146;s forward-looking statements include uncertainties with respect to: the Company&#146;s ability to obtain needed capital; the
Company&#146;s ability to achieve profitable operations; potential declines in Retisert royalties; fluctuations in the Company&#146;s operating results; further impairment of the Company&#146;s intangible assets; the Company&#146;s ability to obtain
marketing approvals for and successfully commercialize Durasert three-year uveitis for posterior segment uveitis; performance by CROs, vendors and investigators; timing of filing marketing approval applications for Durasert three-year uveitis;
acceptability of data to be filed in support of Durasert three-year uveitis marketing applications; maintenance of European orphan designation for Durasert three-year uveitis; potential off-label sales of ILUVIEN for posterior segment uveitis;
successful commercialization of, and receipt of revenues from, ILUVIEN for DME; Alimera&#146;s ability to continue as a going concern; the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; consequences of fluocinolone
acetonide side effects; outcome of dispute with Alimera on commercialization expenses; any exercise by Pfizer of its option with respect to the latanoprost product; the Company&#146;s ability to develop Tethadur to successfully deliver large
biologic molecules and develop products using it; efficacy and future development of severe OA implant by the Company; the Company&#146;s ability to successfully develop product candidates, initiate and complete clinical trials and receive
regulatory approvals; the Company&#146;s ability to market and sell products; the success of current and future license agreements; termination or breach of current license agreements; effects of competition and other developments affecting sales of
products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation;
compliance with environmental laws; manufacturing risks; risks and costs of international business operations; effects of potential U.K. exit from the EU; legislative or regulatory changes; volatility of stock price; possible dilution; absence of
dividends; and other factors described in the Company&#146;s filings with the SEC. You should read and interpret any forward-looking statements in light of these risks. Should known or unknown risks materialize, or should underlying assumptions
prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. The
Company&#146;s forward-looking statements speak only as of the dates on which they are made. The Company does not undertake any obligation to publicly update or revise its forward-looking statements even if experience or future changes makes it
clear that any projected results expressed or implied in such statements will not be realized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter to Stockholders dated December 19, 2016</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>pSivida Corp.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: December&nbsp;20, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Nancy Lurker</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;Nancy Lurker</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman">Document</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter to Stockholders dated December 19, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d318583dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g318583psivida.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;19, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To
Our Shareholders: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As 2016 draws to a close, I want to provide you with an update on our progress at pSivida. Since I joined the Company in September of
this year, I have undertaken a thorough review of the company&#146;s assets and how we are deploying our people, our technology and our capital. I am very pleased with the significant strength of our proven Durasert <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> sustained release drug technology and the scientific, regulatory and manufacturing team here at pSivida, along with the corporate and administrative staff. We have a talented group of people who
are very committed to seeing our products brought to market for the benefit of patients as well as our shareholders. We recently have strengthened the team by the addition of Dr.&nbsp;Dario Paggiarino, our Chief Medical Officer, who joined in
August, and Deb Jorn, a proven commercial and licensing executive who joined in November. Both Dario and Deb bring a wealth of experience from multiple biopharmaceutical companies to enhance the already talented group of people here at pSivida.
Together, we are keenly focused on <I>executing</I> our operating plan and <I>delivering results.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we continue to develop our novel sustained
release drug technologies, we are shifting the deployment of our efforts and capital more towards our proven Durasert technology for small molecules and with<I> </I>established drugs that are already approved by the regulatory authorities. This will
allow us to take on less technology and regulatory risk, while potentially bringing products to market faster. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have three programs that are
well positioned to achieve multiple significant catalysts during 2017. In addition, a key objective for our team is to increase the number of partnered collaboration programs based on our unique technologies as the year progresses. A brief review of
progress since our third quarter report and conference call with investors follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Durasert three-year treatment for posterior segment uveitis met
its enrollment target in the second uveitis Phase 3 trial of 150 patients in September. We continue to expect to complete the readout from this second trial by <FONT STYLE="white-space:nowrap">mid-year</FONT> 2017. The first Phase 3 study data was
positive and highly statistically significant and will be used in our E.U. marketing authorization application, for which we continue to target a first half 2017 submission. Our team is actively pursuing a partnership to market the Durasert
three-year treatment for posterior segment uveitis in Europe, and as developments merit we will update you on this key strategic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">480 Pleasant Street</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Suite B300</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Main: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-926-5000</FONT></FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Watertown, MA 02472</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Fax: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-926-5050</FONT></FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">Web: www.psivida.com</P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercial effort. At the same time, should our second Phase 3 trial also prove to have positive results, as we expect, we remain confident in our ability to file a New Drug Application (NDA) for
this product to the U.S. Food&nbsp;&amp; Drug Administration (FDA) during the second half of 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the three-year Durasert treatment, we
have begun a development program for a next generation Durasert <FONT STYLE="white-space:nowrap">bio-erodible</FONT> shorter duration treatment for posterior segment uveitis. We continue to plan to begin
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> safety and PK studies of this product candidate in the first half of 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Hospital for Special
Surgery (HSS) and pSivida investigator-sponsored clinical study of a Durasert implant to treat severe Osteoarthritis (OA) of the knee continues. The implant is designed to provide long-term pain relief for this condition, which, if effective, could
potentially result in the delay of knee replacement surgery. The study is an open-label, single dose, safety and tolerability study of the screw implant to deliver dexamethasone, a corticosteroid previously proven to provide pain relief in knee OA.
To date, three patients have received the implant and full enrollment will be reported when achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are encouraged by the progress the
team has made in identifying and pursuing additional collaborations with drug developers for our Durasert and potential Tethadur technologies and in <FONT STYLE="white-space:nowrap">out-licensing</FONT> our EU rights for our Durasert Uveitis
product. As developments get finalized, we will announce additional collaborations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we move to advance both the clinical and commercialization
efforts of the company, we also have taken a hard look at our infrastructure and costs and have implemented actions designed to reduce administrative costs over the long term. At the same time, we are expanding our efforts to educate investors about
our company, its progress and its potential. I&#146;ve just finished a series of meetings last week in the Midwest and we are planning for a very full schedule during the JP Morgan Healthcare Conference in San Francisco January <FONT
STYLE="white-space:nowrap">9-11,</FONT> 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In summary, we are very excited about our potential to build value over the next year. Specifically, our
goal is to achieve the following catalysts by this time next year: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Submit E.U. marketing approval application for Durasert three-year treatment for posterior segment uveitis </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Enter into a strategic partnership to market the Durasert treatment for uveitis in Europe </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Announce results of our second Phase 3 clinical trial in posterior segment uveitis by mid year 2017 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Submit NDA to the U.S. FDA for Durasert three-year treatment for posterior segment uveitis in the second half of 2017 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Announce <FONT STYLE="white-space:nowrap">24-week</FONT> post-treatment results of HSS investigator-sponsored study of Durasert implant to treat severe OA </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Enter into additional collaborations with drug developers for our Durasert and potential Tethadur technologies </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g318583g1220051110472.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g318583psivida.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to reporting on our progress as details are finalized. If we can answer any questions, please
contact our investor relations team at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-850-6020</FONT></FONT> and thank you for your continued support of pSivida. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Best wishes for a healthy, happy holiday season, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nancy Lurker
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President&nbsp;&amp; CEO </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">480 Pleasant Street</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Suite B300</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Main: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-926-5000</FONT></FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Watertown, MA 02472</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Fax: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-926-5050</FONT></FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">Web: www.psivida.com</P></TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g318583g1220051110472.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g318583g1220051110472.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& ((# 2(  A$! Q$!_\0
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IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g318583psivida.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g318583psivida.jpg
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M,;>8?K,E5)SGCEE4H5           !0\X<W7T"*K2/UIR]GND7TKD
M      *##EWHJV'K>'V[QUWLT?>N0             %,(CLXG%_7T7:7'W\K
MULGUEZ              /!^>W<\SL<>1W/QM]I4^MW6!9>L@  !3 !E4
M    B^?%X-[CF.R^0Z*8*V1H-I32I2=!7(  4PTVPK-.L*SZ8SX8V*).WFMM
MM4G5^Y0+*H*$06427ZR77(4(?LX<PUDP #E?HZ?F3I*?]%N ZS5K*BS7A*WR
MLMP-;]O/4Y/EJ<GPR?GO,57-A'I.2G/FNMJS0C*XH9)J+S!R(N&V]=ZB^PT2
M5XT-ZA^\7V435I'CF/+>-Y\?HBCL8JLHE#?84C?(?OQ3UW/PM<U_Z:?.NOA?
MI>2WFKN-[K;8"$;6#;[8F.JFZ=+\8^FQMXTAX21%\;8KA>^?K*%-?QA=<_&V
M]ATC0V6+]=85M8.%]_.;Z>?&%C$GFEL-=]_. +NND6OE;+X>OUQGG^[K>P>7
MN>)>PYZ'+>!^F?SKKX9Z7D]BASI1I;^H(1M8.TQO:1(4C%^FO/EW6R;'\))J
M+RK%"%.CY66:+I(WN*&0*;HN?KNMQ^^O4'/6W,'15,O5<S';ZR]63/EERKT=
M38[:RY6S/1SY=5W;W)7O(/4T< 7U7^AO ]5K5G2:U-@S[RO7^LA"-M!C>;&V
MCP]<?OK.51/P\RKP,J'Z*8?;7>4J7H-*L:K?:RW@VW@Y+SVF"LF07;P9IJIW
M.%[5WNF_HR_CO;;ZXSTU]8SK,CRZQYRV@6YK>.^NH.O>3Z&7Z_>$^EY:9.<Z
MC;(,[UE&,^+L<?VVKP]  P9  !@R#"A0]'@]9,*%6?+'LPWKI^</T#E-]@3N
M]N)Z"'NAYRS]-)>H.AR?CZLA4      %#2//UO\ .,1KG+[8Q6,_#&;[.+#&
M<IG&6VTS>=>2^FIX&O:_KGE+R9*N1%5Y17>GIOU7:YR-(KD      !0UC3?Y
ML_+#[94+W.,]MI&WG[9G.NQ;:7V<8[?7@[M*&SWSVCR%UN,?;2;&M^&^,Q'D
M9N-)O//T^N,UQGZ,5     *   %MC-SG J4PU&1Y\:==3^L[]2\S9RC7>V/]
M?.S]-/>-KG3>ZTV^V%05        *%0"@PP7KKS%T=?I,W24:R3,U3)W6)O]
M #XEOG-WJ^F<           4&&@S/.,+/PUR1BYTWVN+Z[!X;;!X;9_PSG//
M'H             %,/CG)CZGH            /_$ "X0  $$ @ $! 4$ P
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MD?=3LAZ7;=;(5!,+KHR8XI,J*K7-K3X1E+)3C[PS<HYFI@?#!471%OA$VE+
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M;Z/.'9"0V\0W+>D"X*[.7^GM1- 6BBPK!)A?%@DT0EI-D(I1?]> _\0 11
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M?)6$D>9_V*BN;>7Y[F@0 & (/!Z[W$C\E'LD/X*+<H]2_]H # ,!  (0 Q
M !  "M+5<            1E>.B            3_ /8             $<HX
M              \;8              $K_X   #;@        3,C   ;I_M@
M$+ !  $D] %'%K4;XDEQ[EB[YIX 59KT<H3F"C0;MZ/+H"W>@-#P-@:9F1MB
M,W #MV(?3Z+<>OMPC::O!5LOMIL]C[?KZ[\W*#L       HKEQ:+P,[#
M   $>> LMA3P8I1U     $LLDU@^8'L$ME        $ $[X4<D=P
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MTU_*@O0O31/QB1#)80HS>VT:/[!8Q0C:G0(H]>C*^#_,%A%T#+B.0=;O']P
M81B.[?48;4<<R_J0?T%/Y6J ,2,^L"=X%\..M5MB,AD&V0=GIXJ< %NKTE;-
M3OX 4%<7(:7GR2(D8M'9!IX, (JGNP 0" % % !H,A/&<[@X;G%T6X.OD%F!
M5[O)^2"9"*.2:LF] #7 A)"5+@QZ_J:1K<E00%2:\?&:/3XP[B8<X8B3*D>C
M@G $JF@6)T8)&I5K5E9,?+_!411%0(!(Q%08&!"$*$$O[P-SJ=T0 <!:)&.X
M1)!&9*42DCG*I[SWXEA4:$B.4,&(I5(:/1>V-RS#ZN%'@<C& @*R73J2 H"\
M&M1Z5$8XC'AHHGU8_61QT'7">^#5 ]!!178%8JE7IJ%*.%]A@MTWTT+^A3T7
MT_Y9 LZ/BYOM$U%P$&;5YE:W7*Z YE"(@879M4P;T 848"#7#2$Z"2,!O<Q3
MB"&*(VO6\1\,=V(RG"[69CB _1RL<ZDX95"N;A!B,YJ<C3,7B,[G9Z1'^L$"
M?:8X$04[0+R-*"@0(8U/$,ZQN0# ]LY6I=BO +7@*(72> /3PQZ7C&C$AI77
MJ*%A" EF19:;-I#(DI0 2$ @@! % &IBLK_2,R:='(#E_ SEE6[APG1?3M]H
M:D0=!AYFJ2@2E2TCM9P:0.XNB0H^N42&6R.Z0$FV.%4:?T@AXG'$*1Z&.WV<
M@%B#=1<>(Q.I6=RSS@%9'2H^R%PC @H)1'V']F'WQ_/TW$>1%760-DS<5#".
MG!\1XP1WEDED @*O_<13$R K'2I,:CUQ2"U(T "BZ/,@-X5X]HPG]9/9(8Z:
MZ8U2E(Q@,;$+>:8)="]P23>L'*\,=N(S')"N,(6=3;AX4QEKHP53"1#*6)>6
M>&@@"S@6R2&:8<P+ %P;20K55M<KVSVY"-7Q03@FG#P)XQBK/"@"&4"F)"Z3
M%@KCXP<(;HAT#T6@&<?.7/6CG"S-?O6 !(GB.X#$V)%":ES/H/3&I6T'Q=0/
MV.-!YPEHO)A V BO_P 7" ";1A2)ZZ'0P3743TS;C18$'HEHXIA&T<C0@O>*
M=G+:+301+M6/?C$(1 A8C8D<1#_-.&()H$CP]OFK%+<0!,(P _YN9D^V::0T
M('H2R[HSS3I )2291PO'6>#TJ !! 22<!P+<@(%<S77UR/FC+"+P$/K1O@'"
M?.R:@3"&FQ$!9C.:.,A J!,:,8BM<QFAA!>1'CXQB1;%"K-2HZ8@PDO@W%\3
MC:K,1X]HPBXPXQRC1;J=\.\P @9<00EC"69!Y"*H*!=&C!1D]I$#F*F&&'>C
MTR$]PHM A$D%%6 Q#Z<07CD2\-W5[ %<3Y(%1]$(Y(.$D"ZL3,&[P?I:*:[@
M?]/-#C^E,GM;0E3ADBVXL$U#TDQ=,]0SP<9-&>B?U$84K4,IV1(T];)45 MG
MW&YCK&1ALZD0G3+[[>D,-+(X]%.%WGDXCQ_$Z!H#_@U'LS6L19]*LBX04K(C
MM[:R#[Q&:\9!][9$>/:,@^]L@/O3 #C60'W60'CX_B#TCQK(#Q\?Q =H\9X"
MTM!'5XQ*"6@*L=C%=(CQ$=L7A0Y 1V"9"2$TH3PF*:J"R4 BI6:\X1(QNHZ3
M)C$"J +4!ZEUYQ44%R@CLL*K45TB,!($@3!".C7<X*(,4%^^3JY2*<1T)I@6
MC8DZ@YQAW!A&2D"(E(XA&&4+(.&DYZ1Q7=&[5=4)'3N&-V#$4"&!M H;*81P
M?;XR/;-?^_'WC.'Q!5X0-%,]64CE)>: =<&-FL-/-+$48G7>)1F\340$JVYF
M6L!=!K$[8]F<J.RHD TA$K"5_"*7.Q6)A#R>8(&R* 2X%"!9?2@5>EJTV6!F
M;^S!@ E(!)W)MEP" H 3S=UB4A_R,<>F,,?06(>H9$\#[S@'[(-."$RC<K1N
M* C&!(9;H+":11WCCDPBRHY40O92..0>FQS-I^5_N4$,0N@EME^!<5592,R0
MZA/P7?[%/SA2@B&K(C!4242K1,>I)!B\I&8AE6A1K,Y :P0L++")DX$H0*Q6
M .=00A] !P3>\(D09 '("@Z3<9&NWQC0V&=C+[*ZA2)Q"@N_\3O"(&\$GDP-
M(!2C:BG&??UD'S4@%8E:;?",AULJT( <OD;980JKMD*-&F6 "+'TIA(@)Y-I
M4O <*PPT!0BO;J:=)B-7,P%J.P.23O@@;KK<1WP<"]<CN)\AAH0=-$C]?[RD
MN.'I[IQ< OCAKSA-A.EU$=C"8^U_Z??UD9KM'B(SX]HR(\9KM[:SX]LMV@$O
M#BK/3(CM[:S7;VU_#1Z?&'G5?1!,5CGL<ZP)S*# 0#1+$PQ,.(&8,IB9 .L@
M3!"TP) %"VV5.C0%1%1'"1'^8^0E[:O(GM8MH"Q =)5/;.=@Y&:]99[$"NO&
M0$B[$*[[P6 AT[=\UV]LF.WM^%KM[:_JE>GQE8L@/P,:[4@148/6R@M#P423
M[9.&,(Z1A4)$:T'I> :%2"C5 @(\!AND $NJ1G2KLPN7A!KA2#SFNWMK/OZS
M7CXPWT\E>@5>#)6O06)TD\-8:*P7"#MQ/?\ )%10:1)$TB=(PD34$%YDOE1L
MWEU^+%IT>0/Z8HTXMT<CCN8&,$:&E7:G<P(@"()%!9]\6*@"=OFN'G%4>!(0
M=RSX(8B"X4E ZDI?\,J)D,0= @_-:^],4^S/+C8L'+9'<<(( %   CH'Y(#_
MQ  H$ $  0,$ 00" P$!       !$0 A,4%188%QD:&QP1#1($#P,/'_V@ (
M 0,  3\0_A]5$<15F2)I4N _VE(B(!O^J$:1W1!K[?JGX_M8ZJ(XBI!,.C-*
M1(:?MR\XJPA?YEHB*&.J^OQ]?VBW$5$E+6^4_:A][>YIWF@0$C+_ +!6.O[I
M1;JF%%0M9\*.N[T&KQ^Z"&-3J\M8Z_O%!"XMNO+'%9#=<.LK>_+0$( 4EPTZ
M4P&6!>?%$0)C3^].6#Z5=R9> 4-M[?% E)&+N UBV*GW)1N+RF)0'$5B-(_X
MQ[5$=5'M6.OZ4%L%WV/2ISR-$\0E=%C[I,H&3I ]8I2[,[@NWX6#@J?;^85$
M[$P0&)3AU+I5Q0L@9/,!4>BW-&\6.4J'0WZKHHX9D&T#==ICB40\%#N-*EWP
M)H1,D!X_BV5,!-LA-C09J(Z_..J4)! BLW37&/Y7%@1GH/FC>#6U6DL4<Q>D
M:1:."WN*.&1)>H?7\'-D)8F.BL-BN$'##'<5$Q@V?[J:%Y/?<#EBD 65<3$:
M1%1W*;&+D&J5\:%6+!$:5;TJ*O;3FJFR!!6 JWBK0:EX"7V*NPF]E.U[5NJW
MLD,8\V_'U5ZPA"+ X6,%26A 36QG2[7M3XF0"CTMIB9J#@Y?NB;:P:[:<':4
MA@1(1Z^KS40 [_ 9>J9+ST43]^U#(0&)6'JTW"#PLX=N)J(XBI=UO5?JC(8N
M?-6GB ^*VQG#:2?B@=6!/+/W_"SQ'B]!M8C$&@G -JCT^GZJ;%E* B%KA.=*
M1XHW!H\$6H*( 94F%@R,(V=:!'CLAC6VKQ4?'_JU(\ML$]H5(A0 )%@D20NI
MTJ-O#\VO8OA^J$6) G#+U;S%)5) >(JRX&0W= Y6U,2U%+G9^O!6WT^U5E-4
M1I-IZF>JF)!("V0S,8SF]1\'#]5;<5D #HB0D-Z=))$M6%O[4.]\MHPF[OB@
MXO9!&(H]$4_&A9411AN,%L*6S-#(-"-,8NI*MT)#Z-*8=D>E)I@9U)\E&3H0
M7"2]RL=?GT5GND=2 .RR.R5$=43"0EVMOI02!"@6V(<9\T(@5&D-L7VL_BQQ
M%%N*4H(2&S0E\V3;-!#;))YG->Q4%L.(?]FE"NV6TRTZN>E._EQC1-'Q@Y9*
M,V" \6JWB-:2"=EW)-O%(3+,":D+/,1ZT$=5!E8"^E L@&6Z%8FGEP2%-)4C
M5L3H4$#%JH]LWKC$:C\IIG-02);R\7N58&D%00<DGA(*S\5N.D^0A]YI8(P2
M></8J84/TP!Z8K2V+?G1VB#89MZ4%4<F0\RA@HCX:5-A[ 73HTVDFL2N2Y75
M?-!!^ NW!RT FVE @X@D-M5DF@>'C]*MV+7Z$)*/<H$B*3(CP")UIX421B5!
M/!0G!S% (0R#-3[4/%,24&[*#C3RT*1YF)$V)0;9KVBH2UB4MRP&;;TK&0A.
M(BAXAD2@\9-.*@<#6U%^Q8<(VV3KQ3:P)(9"8)!0$@Q?%L:/AFR4!!*C5"?:
MU0B!&\%/T0N  6(98XH( Q!4&2Y]EGT+U:FERI);MO)D](^*C1(PZS>G9:M4
M*U-3CS\5I@0\BP^=&L=?B+"9$L%FK,H5#:2OJL<1^"W5?53'53[5CB*Q7U6.
MJQU4QU6.OQ@VJYQ%8H^*QQ&E>U?51'$5'45CBKAJ$>2/:H+RU#FVO9>I^L>F
M:3X:(3<=.*<:SJ:+7I3VPLQN:B:S34D'(.O6S6.(K%?7_<M2M@=Q!@S:<4!&
M<:(_52!@B2(AQM.E;'@ 'Q0[>P*@&["6TIM*+,,"@:$[ZT@F)+@G9$%6!)T"
M8'!..:@A",(A$-MJ #"M\^U%NJP!.#1^S#U5IU42 ,#=T=U/6'#JC">*;G8T
M+CCDUJ D^CQ&*)'C.)XVKQ_0QU062ID<A\;4 V#2"K<:'P,[U&X-H'WXI+."
MPP8 *<,1G.UVT46XI0 D6.CB&I(S8(0!;$NU36$L;;'16.(HXH<)2=C.^EL)
MW,-+CE#]/FAB6<G)]4_A-'4Y&EI$6$NAR5(FB:?[XJT#(:-__*@%AXH\5$>(
MH.<5CK_ICB*QQ'XQQ^/JL<4H!9+ V*^J^OP6CBE80GD1^J6 P3&G]'BD@D?[
M%#(!T=?%?!5SN;V4PTPT3]4D;EN(JPO$;5CJI]J^J^OZ7U_#'$46I+ 4],@P
M"X<GZJV+I& (QI&1J !#=OZ_NL&R-&S4FC7U^0="H@NQP9I= @?V,<11M6=Y
M!;UC-*W@YM%&2P.ZL8D;0U;'U0[8CBB3*>"L8P5CC^Z'M4&U &D17U_9_\0
M*1 !  $#! $#! ,! 0       1$ (3%!46&!<9&AL1! P? @T>'Q,/_:  @!
M @ !/Q#^&.(J<6?% "[:1ZF+>)J"-RU/4BI$!.2;X?S6@=BPH/.QH_ZM01I$
M?=8XBI]JA#NABW#+['-1_$+Q0)J#8ZJ<,S$WQ)[BDCY! X! ?0MU],<?<XZH
ME0$L@!\110TS=6\/X^JI4A$9S!8!MJZ5QRE@:3NY]*". ^]QU6FU7Q#=B XN
M='=0=% PZ :JVXJ*9&+P@,>=Z"/OFQXJZ*ULK^5SP<U"( ., !8C2"EE)4-
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)TI98\M8^Y__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
